According to Stock Talk (@stocktalkweekly), Wells Fargo has upgraded RxSight (RXST) to Overweight from Equal Weight, raising its price target to $25 from $17. The report cites RXST’s strong first-mover advantage in the rapidly growing light adjustable lenses market, noting significant adoption since its 2019 launch. This upgrade signals increased institutional confidence and potential capital inflows into RXST, which could drive short-term trading volume. For crypto market participants, positive momentum in medtech stocks like RXST may translate into broader risk-on sentiment, supporting correlated digital health tokens and blockchain healthcare projects. Source: Stock Talk (@stocktalkweekly), May 19, 2025.